The noradrenergic system is involved in the etiology and progression of Alzheimer's disease (AD) but its role is still unclear. Dopamine beta-hydroxylase (DBH) as a catecholamine-synthesizing enzyme plays a central role in noradrenaline (NA) synthesis and turnover. Plasma DBH (pDBH) activity shows wide inheritable interindividual variability that is under genetic control. The aim of this study was to determine pDBH activity, DBH (C-970T; rs1611115) and DBH (C1603T; rs6271) gene polymorphisms in 207 patients with AD and in 90 healthy age-matched controls. Plasma DBH activity was lower, particularly in the early stage of AD, compared to values in middle and late stages of the disease, as well as to control values. Two-way ANOVA revealed significant effect of both diagnosis and DBH (C-970T) or DBH (C1603T) genotypes on pDBH activity, but without significant diagnosis ×genotype interaction. No association was found between AD and DBH C-970T (OR=1.08, 95% CI 1.13-4.37; p=0.779) and C1603T (OR =0.89; 95% CI 0.36-2.20; p= 0.814) genotypes controlled for age, gender, and ApoE4 allele. The decrease in pDBH activity, found in early phase of AD suggests that alterations in DBH activity represent a compensatory mechanism for the loss of noradrenergic neurons, and that treatment with selective NA reuptake inhibitors may be indicated in early stages of AD to compensate for loss of noradrenergic activity in the locus coeruleus.
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Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by memory loss and cognitive impairment. Because aging is one of the main risk factors for AD and due to the generalized increase in life expectancy, the prevalence of AD among individuals above 65 years of age is rapidly increasing and AD represents a major public health problem worldwide (Alzheimer's Association, 2010).
None of the many hypotheses of the etiology of AD has successfully explained all of the features of the disease. AD is a multifactorial disease with a complex interplay of many genetic and environmental factors resulting in a network of interactions that still have to be deciphered.
Neuroimaging studies have revealed brain atrophy in the neocortex, hippocampus, and several other brain regions (Cummings, 2004) . Dysfunction in cholinergic system was recognized early (Coyle et al., 1983; Giacobini, 2003; Lyness et al., 2003; Wenk, 2003) . The loss of serotonergic and noradrenergic nuclei in the brainstem has also been reported in patients with AD (Garcia-Alloza et al., 2005; Herrmann et al., 2004) implying a role for these neurotransmitter systems in the etiology of AD (Lyness et al., 2003) .
The noradrenergic system has two main projections, one originating from noradrenergic cells bodies in the ventrolateral tegmental area that is involved in sexual and feeding behaviors, and the other, originating from the locus coeruleus (LC), associated with learning, memory and cognitive functions (Grudzien et al., 2007; Heneka et al., 2010) . The loss of noradrenergic neurons from LC correlates with the increase of extracellular amyloid β protein (Aβ) deposition in mice (Heneka et al., 2010) , neurofibrillary abnormalities in early stage of AD (Grudzien et al., 2007) , onset (American Psychiatric Association, 1994; Counts and Mufson, 2010) , and duration of dementia (Counts and Mufson, 2010; Forstl et al., 1994) . In AD, reduced concentration of noradrenaline (NA) has been reported in many brain regions (Herrmann et al., 2004; Hoogendijk et al., 1999) . In addition, increases in cerebrospinal fluid 
